The Children's Hospital Of Philadelphia

The Children's Hospital of Philadelphia Research Institute, operating as Children's Hospital of Philadelphia Foundation, is a nonprofit pediatric research and teaching hospital based in Philadelphia, Pennsylvania that functions as a federal grant recipient across the National Institutes of Health portfolio, with a small footprint of federal service contracts and clinical consultation work.

The organization operates primarily as a grant recipient rather than a federal contractor. Across a source window spanning 1976 through early 2027, Children's Hospital of Philadelphia Research Institute has received 1,668 prime federal grants and a smaller number of prime contracts—primarily purchase orders for clinical services and research support—alongside 1,004 sub-awards as a sub-recipient under larger prime grants. The organization holds no general-purpose IDIQs or government-wide vehicles. Recent annual federal grant volume has ranged from 187 awards in 2023 to 399 in 2024; activity in 2025 was 328 awards. The combined potential value across all awards in the source stands at $252.1 million, though obligated dollars across all awards total $5.28 billion, reflecting the presence of multi-year, multi-million-dollar research programs and substantial sub-award pass-throughs.

Capability portfolio centers on biomedical research, clinical investigation, and translational science in pediatric diseases. Concrete work spans rare genetic disorders, immunotherapy (CAR-T cell engineering for leukemia and solid tumors), hemoglobinopathy treatment, infectious disease, cancer genomics, neurodevelopmental disorders, and epidemiological research using electronic health records and clinical cohorts. Representative prime grant awards include a $2.71 million National Heart, Lung, and Blood Institute program grant (September 2026) on lipid nanoparticle delivery of hematopoietic stem cell therapies for sickle cell disease and thalassemia; a $708.565 thousand National Institute of Neurological Disorders and Stroke project grant (September 2026) investigating photophobia and light exposure in adolescents with migraine using wearable biosensors; and a $1.87 million National Institute of Diabetes and Digestive and Kidney Diseases cooperative grant (June 2026) applying integrative proteomics and metabolomics to identify mechanisms of adverse outcomes in pediatric chronic kidney disease. On the contract side, the Centers for Disease Control and Prevention issued a $125.910 thousand purchase order (September 2026) for acute flaccid myelitis case classification and neurologic consultation services, and the Federal Aviation Administration awarded $168.750 thousand (March 2025) for Center for Child Injury Prevention Studies membership.

Federal customer concentration is dominated by components of the Department of Health and Human Services National Institutes of Health. The National Institute of Diabetes and Digestive and Kidney Diseases leads both total dollars ($85.3 million combined potential value across 208 awards) and award count among top grantor divisions. The National Institute of Allergy and Infectious Diseases ranks second by potential value ($52.7 million across 156 awards), followed by the undifferentiated NIH aggregate pool ($33.3 million across 391 awards). The National Heart, Lung, and Blood Institute provides $15.6 million across 264 awards, and the National Institute of Child Health and Human Development contributes $6.3 million across 169 awards. Together, these five entities account for 77% of the organization's combined potential value across recent awards. The Centers for Disease Control and Prevention, National Cancer Institute, National Institute of Neurological Disorders and Stroke, and Defense Health Agency round out the active federal portfolio, though at substantially smaller funding levels. The funding distribution reflects the organization's research identity: NIH extramural research programs drive the mission, with only occasional federal service contracts (including a small number of HHS IDIQs for task orders in health services research and support activities).

The organization competes almost entirely in full-and-open federal grant programs rather than set-asides. No SBA disadvantaged-business certifications or set-aside designations appear in the source. As a nonprofit teaching hospital and research institute, the vendor does not carry 8(a), HUBZone, SDVOSB, or WOSB certifications.

SCI-reportable service contract activity is modest and declining. Across FY2022–FY2025, the organization invoiced $4.1 million on federal service contracts captured above the $150,000 reporting threshold, with $1.3 million in FY2022, $1.9 million in FY2023, $852 thousand in FY2024, and zero in FY2025. Government-paid hourly rates on prime SCI contracts run a median of $213.82 per hour, with a range from roughly $76 per hour (10th percentile) to $457 per hour (90th percentile), reflecting clinical and research specialist labor. FTE trajectory on SCI-reportable work shows 7.9 FTEs in FY2022, declining to 5.8 in FY2023, rising to 9.6 in FY2024, and declining again to 4.1 in FY2025. The organization performed all SCI-reportable prime contract work in-house; named subcontractors appeared only on sub-recipient awards, not as subs on the organization's own service contracts.

Teaming posture reflects the organization's role as a research recipient and academic medical center. The organization acts as a prime recipient on the vast majority of its federal grants but engages extensively as a sub-recipient on larger multi-institutional grants. Notable sub-award relationships include subordinate roles on cooperative awards led by The Trustees of The University of Pennsylvania (more than 100 sub-awards in the source window), Emory University, Vanderbilt University Medical Center, and other research universities and teaching hospitals. This sub-recipient activity represents collaborative research partnerships rather than vendor-supplier relationships; the organization contributes scientific expertise, patient cohorts, biospecimen collection, specialized testing (e.g., proteomics, genomics, microbiome analysis), or clinical sites to multi-center consortia and studies. Named sub-recipients to the organization's own prime grants include The University of Pennsylvania (methodological and collaborative research support), Johns Hopkins University (heterotopic ossification research), and Stanford University (biospecimen validation and clinical expertise), among many others. The organization also maintains clinical trial networks including the Global Leukodystrophy Initiative Clinical Trials Network and participation in the Pediatric Research using Genomics and Innovative NeTworks (PEDSnet) consortium, through which it contributes patient data and research coordination services.

Recompete exposure within the next twenty-four months is limited. Two hundred twenty awards with ultimate completion dates falling within the next twenty-four months carry a combined potential value of $1.3 million, representing a small portion of the organization's active portfolio. The organization's grant-heavy profile means most awards are investigator-initiated research projects with extended performance periods and natural completion cycles rather than competitive contract vehicles facing simultaneous rebid windows.